About: Clinical outcomes in breast cancer patients with HIV/AIDS: a retrospective study

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Clinical outcomes in breast cancer patients with HIV/AIDS: a retrospective study Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Clinical outcomes in breast cancer patients with HIV/AIDS: a retrospective study
Creator	Gomez, Alexandra Hurley, Judith Montero, Alberto
topic	covid:a05a7e8a28e7de7d685db8f4989aec8f3e8dfa41#this
Source	PMC
abstract	The purpose of the study is to describe what is the presentation of breast cancer in women with HIV, their tolerance to therapy, the most common complications of treatment and their outcomes. Retrospective chart review of patients with HIV diagnosed with breast cancer between January 1, 1989 and December 31, 2013 at the University of Miami/Jackson Memorial Hospital (UM/JMH) 47 females and 1 male were included in the analysis. The median age of diagnosis was 46 years (IQR 41–52) and 64 % of the women were premenopausal. Median CD4(+) count was 330 cells/µL (IQR 131–589 cells/µL). 41 % had AIDS at time of diagnosis. 94 % of patients presented with locoregional disease and 6 % with late stage breast cancer. 52 % had ER(+) tumors. 6 % had HER-2/neu tumor expression and 21 % had triple negative disease. The 5 year PFS was 50 % (95 % CI 34–64 %), the 5 year OS was 44 % (95 % CI 29–58 %), and the Breast cancer-specific survival was 57 % (95 % CI 40–70 %). Death was attributed to breast cancer in 22 patients, AIDS progression in 6 patients, other medical condition in 1, and for 4, the cause was unknown. Serious adverse events were documented in 46 % of patients treated with chemotherapy. Targeted therapy was well tolerated. Patients with HIV/AIDS and breast cancer pose a major challenge for oncologists. Surgery, radiation, and endocrine therapy are well tolerated. Standard dose chemotherapy can have life-threatening side effects which can be managed with growth factor support and antimicrobial prophylaxis. All cancer therapy can be given while continuing with antiviral therapy at full dose.
has issue date	2015-02-07(xsd:dateTime)
bibo:doi	10.1007/s10549-015-3275-9
bibo:pmid	25663516
has license	no-cc
sha1sum (hex)	a05a7e8a28e7de7d685db8f4989aec8f3e8dfa41
schema:url	https://doi.org/10.1007/s10549-015-3275-9
resource representing a document's title	Clinical outcomes in breast cancer patients with HIV/AIDS: a retrospective study
has PubMed Central identifier	PMC7102268
has PubMed identifier	25663516
schema:publication	Breast Cancer Res Treat
resource representing a document's body	covid:a05a7e8a28e7de7d685db8f4989aec8f3e8dfa41#body_text
is http://vocab.deri.ie/void#inDataset of	https://covidontheweb.inria.fr:4443/about/id/http/ns.inria.fr/covid19/a05a7e8a28e7de7d685db8f4989aec8f3e8dfa41
is schema:about of	named entity 'cancer therapy' named entity 'antimicrobial prophylaxis' named entity 'IQR' named entity 'Patients' named entity 'patients' named entity 'diagnosis' named entity 'diagnosis' named entity 'adverse events' named entity 'CD4' named entity 'chart' named entity 'Breast' named entity 'growth factor' named entity 'median age' named entity 'DIAGNOSED' named entity 'CD4' named entity '589' named entity 'therapy' named entity 'Jackson' named entity 'therapy' named entity 'dose' named entity 'oncologists' named entity 'presented' named entity 'breast cancer' named entity 'tumor' named entity 'tolerated' named entity 'breast cancer' named entity 'pose' named entity 'patients' named entity 'study' named entity 'treated' named entity 'breast cancer' named entity 'HER-2/neu' named entity 'medical condition' named entity 'HIV/AIDS' named entity 'Breast cancer' named entity 'breast cancer' named entity 'University of Miami' named entity 'JMH' named entity 'median age' named entity 'Targeted therapy' named entity 'adverse events' named entity 'chemotherapy' named entity 'breast cancer' named entity 'breast cancer' named entity 'toxoplasmosis' named entity 'HIV/AIDS' named entity 'breast cancer' named entity 'standard deviation' named entity 'breast cancer' named entity 'breast cancer' named entity 'Breast cancer' named entity 'life-threatening' named entity 'HIV' named entity 'AIDS' named entity 'CD4' named entity 'Blood transfusion' named entity 'prognosis' named entity 'chemotherapy' named entity 'neoadjuvant' named entity 'African American' named entity 'chemotherapy' named entity 'breast cancer care' named entity 'HIV/AIDS' named entity 'HIV infection' named entity 'chemotherapy' named entity 'AIDS' named entity 'HIV' named entity 'Progression-free survival' named entity 'breast cancer' named entity 'CD4 count' named entity 'life expectancy' named entity 'risk factors' named entity 'historical data' named entity 'viral load' named entity 'lymph node involvement' named entity 'breast cancer' named entity 'CD4'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software